GRASS (Grass MATA MPL Real-world Assessment Study)

Allergy Therapeutics

Status: Enrolling

Conditions: Grass Pollen Allergy

Treatments: Drug: Grassmuno®

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT07412990

GRASS-NIS

DRKS00039005 (Other Identifier)

Details and patient eligibility

About

Objective of this non-interventional study (NIS) is to collect data on the use of Grassmuno® in routine clinical practice.

Enrollment: 1,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

At the physician's discretion and based on the current Summary of Product Characteristics (SmPC), study participation may be offered to patients who

• are male and female patients
• are 18 years of age or older
• treated in accordance with the SmPC of Grassmuno® for IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis (without asthma or with well-controlled asthma) triggered by grass pollen.
• Patients will only be enrolled in the study after the treatment decision has been made

Exclusion Criteria:

At the physician's discretion, the study should not be offered to the following patients:

• Patients who are not sufficiently proficient in or do not adequately understand the German language, as this would prevent adequate comprehension of study-relevant documents.
• In addition, patients should not be included if any of the contraindications listed in the current Summary of Product Characteristics (SmPC) are present.

Trial design

1,000 participants in 1 patient group

Grass Allergic adults

Description:

Adult patients aged ≥ 18 for whom pre-seasonal subcutaneous allergen immunotherapy (AIT) with Grassmuno ® is indicated for the treatment of IgE-mediated moderate to severe allergic rhinitis and/or rhinoconjunctivitis with no asthma or with well-controlled asthma elicited by grass pollen allergy

Treatment:

Drug: Grassmuno®